Novartis Ag

Novartis Pharma Gmbh

Lászlo Révész

Achim Schlapbach

Reto Naef

Philipp Janser

Peter C Hiestand

Guido Koch

Birgit Bollbuck

Lukas Oberer

Rudolf Wälchli

Hans-Ulrich Naegeli

René Hersperger

Jörg Eder

Rudolf Waelchli

Alastair DenholmMritain

Rudolf Wálchi

Hans-Jorg Roth

Alastair Novartis Horsham Research Ctre Denholm

The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.

Tetracyclic lactame derivatives

A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent. 

2-aminopyrimidine derivatives and their medical use

Compounds of formula I and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNF&#x3b1; and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF

Compounds of formula (I)and pharmaceutically-acceptable and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNF&#x3b1; and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use

The invention relates to a process for producing pyridinoline and deoxypyridinoline crosslinks and derivatives thereof and their use in determining connective tissue disorders in humans and animals.

Pyridine derivatives

Tetracyclic triterpenes

Growing community of inventors

Therwil, Switzerland

Lászlo Révész